March 30, 2021 News by Marta Figueiredo, PhD Kesimpta Approved in EU as At-home Injectable Therapy for Relapsing MS The European Commission has approvedĀ Novartisā Kesimpta (ofatumumab) as the first self-administered, at-home B-cell-targeting therapy for adults with relapsing forms ofĀ multiple sclerosis (MS) and active disease. Active disease in these forms, which include clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS),…
March 24, 2021 News by Forest Ray PhD Health Canada OKs Self-administered Kesimpta for Adults With Active RRMS Health Canada has approvedĀ Kesimpta (ofatumumab) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) who have active disease, as defined by clinical and imaging features. In contrast with other B-cell-targeting therapies used in MS, patients can self-administer a precise dose of Kesimpta at home using the Sensoready…
February 17, 2021 News by Marisa Wexler, MS Survey: Patients, Nurses Prefer Sensoready Autoinjector Pen People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey. The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at…
February 1, 2021 News by Marisa Wexler, MS CHMP Favors Kesimpta for Adults With Relapsing MS in Europe A branch of the European Medicines Agency (EMA) has recommended thatĀ Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows…
December 21, 2020 News by Joana Carvalho, PhD Kesimpta Available Through AllianceRx for US Patients With Relapsing MS Kesimpta (ofatumumab), the first self-administered B-cell therapy to treat relapsing forms of multiple sclerosis (MS), is now available via AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies operating in the U.S., to patients living in the country. The specialty pharmacy ā which focuses on serving…
November 2, 2020 News by Marta Figueiredo, PhD Ocrevus Still Reigns for Progressive MS, Spherix Reports, But Challenges Noted GenentechāsĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed treatment for people with progressive forms of multiple sclerosisĀ (MS) amongĀ U.S. neurologists, according to the latestĀ Spherix Global Insightsā report. However, NovartisāĀ MayzentĀ (siponimod) āis beginning to close the gapā with Ocrevus among those with active secondary progressive MS…
October 7, 2020 News by Steve Bryson, PhD Rituximab Seen to Affect How B-cells Return After Treatment Stops Rituximab, an investigational B-cell depletion therapy that target CD20 to treat people with multiple sclerosis (MS),Ā has significant effects on the characteristics of B-cells that return after treatment is stopped, with cells being less mature yet more activated toward a pro-inflammatory state, a study showed. Treatment also…
September 11, 2020 News by Marisa Wexler, MS Progressive MS Trial of Kesimpta Not on Horizon, But Other Possibilities in Works Novartis is not planning to open a clinical trial ofĀ Kesimpta (ofatumumab)Ā as a potential treatment for primary progressive multiple sclerosis (PPMS) anytime soon, a company executive said. But it is well aware of the “unmet need” for therapy options among this patient group, and is exploring avenues. “We do…
September 11, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 – Novartis to Present Latest Data on Kesimpta, Mayzent and Gilenya Novartis will present the latest clinical data on three of its approved multiple sclerosis (MS) therapies ā Kesimpta (ofatumumab), Mayzent (siponimod), and Gilenya (fingolimod) ā at the Ā MSVirtual2020 meeting that opens today. The 8th joint meeting of the Americas Committee for Treatment and…
September 10, 2020 News by Marisa Wexler, MS New and Ongoing Trials Evaluating Kesimpta, Including as Switch Therapy Upcoming and ongoing clinical trials aim to expand an understanding ofĀ Kesimpta (ofatumumab), theĀ Novartis therapy recently approvedĀ by theĀ U.S. Food and Drug AdministrationĀ (FDA) to treat relapsing forms of multiple sclerosis (MS). Kesimpta is an anti-CD20 monoclonal antibody, a type of treatment that is thought to work…
September 1, 2020 News by Marisa Wexler, MS Kesimpta Meets Safety, Efficacy and Flexibility Needs of Relapsing MS, Experts Say Kesimpta (ofatumumab) is a safe and effective treatment for relapsing multiple sclerosis (MS), with an ease of delivery that makes it more convenient than comparable therapies, experts say. Developed and marketed by Novartis, Kesimpta was recently approved by the…
August 24, 2020 Columns by Ed Tobias MS News That Caught My Eye Last Week: Kesimpta, Ocrevus and Chickenpox, Generic Tecfidera, UTIs FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS The U.S. Food and Drug Administration’s approval of Kesimpta (ofatumumab) this month is a pretty big deal. Kesimpta is a once-a-month injectable disease-modifying therapy. There’s nothing else like it, because Kesimpta targets B-cells in the immune system. Until now, only…
August 21, 2020 News by Marisa Wexler, MS FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for adults with relapsing forms of multiple sclerosis (MS), meaning those withĀ clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). According to Novartis,…